Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 153

1.

The Fold-in, Fold-out Design for DCE Choice Tasks: Application to Burden of Disease.

Goossens LMA, Jonker MF, Rutten-van Mölken MPMH, Boland MRS, Slok AHM, Salomé PL, van Schayck OCP, In 't Veen JCCM, Stolk EA, Donkers B; research team that developed the ABC tool.

Med Decis Making. 2019 May 29:272989X19849461. doi: 10.1177/0272989X19849461. [Epub ahead of print]

PMID:
31142198
2.

Clinical outcome and cost-effectiveness of a 1-year nutritional intervention programme in COPD patients with low muscle mass: The randomized controlled NUTRAIN trial.

van Beers M, Rutten-van Mölken MPMH, van de Bool C, Boland M, Kremers SPJ, Franssen FME, van Helvoort A, Gosker HR, Wouters EF, Schols AMWJ.

Clin Nutr. 2019 Mar 18. pii: S0261-5614(19)30114-1. doi: 10.1016/j.clnu.2019.03.001. [Epub ahead of print]

3.

Long-term cost-effectiveness of the fixed-dose combination of tiotropium plus olodaterol based on the DYNAGITO trial results.

Hoogendoorn M, Corro Ramos I, Baldwin M, Luciani L, Fabron C, Detournay B, Rutten-van Mölken MPMH.

Int J Chron Obstruct Pulmon Dis. 2019 Feb 18;14:447-456. doi: 10.2147/COPD.S191031. eCollection 2019.

4.

Broadening the Perspective of Cost-Effectiveness Modeling in Chronic Obstructive Pulmonary Disease: A New Patient-Level Simulation Model Suitable to Evaluate Stratified Medicine.

Hoogendoorn M, Corro Ramos I, Baldwin M, Gonzalez-Rojas Guix N, Rutten-van Mölken MPMH.

Value Health. 2019 Mar;22(3):313-321. doi: 10.1016/j.jval.2018.10.008. Epub 2018 Dec 20.

PMID:
30832969
5.

Planning, implementation and operation of a personalized patient management system for subjects with first suspect of cancer (OnkoNetwork): system description based on a qualitative study.

Pitter JG, Csanádi M, Szigeti A, Lukács G, Kovács Á, Moizs M, Repa I, Zemplényi A, Czypionka T, Kraus M, Rutten-van Mölken MPMH, Kaló Z.

BMC Health Serv Res. 2019 Feb 21;19(1):131. doi: 10.1186/s12913-019-3957-9.

6.

What Is the Potential of Tissue-Engineered Pulmonary Valves in Children?

Huygens SA, Rutten-van Mölken MPMH, Noruzi A, Etnel JRG, Corro Ramos I, Bouten CVC, Kluin J, Takkenberg JJM.

Ann Thorac Surg. 2019 Jun;107(6):1845-1853. doi: 10.1016/j.athoracsur.2018.11.066. Epub 2018 Dec 31.

PMID:
30605643
7.

Bioprosthetic aortic valve replacement in elderly patients: Meta-analysis and microsimulation.

Huygens SA, Etnel JRG, Hanif M, Bekkers JA, Bogers AJJC, Rutten-van Mölken MPMH, Takkenberg JJM.

J Thorac Cardiovasc Surg. 2018 Oct 22. pii: S0022-5223(18)32794-6. doi: 10.1016/j.jtcvs.2018.10.040. [Epub ahead of print]

PMID:
30501946
8.

Beyond the clinical impact of aortic and pulmonary valve implantation: health-related quality of life, informal care and productivity†.

Huygens SA, van der Kley F, Bekkers JA, Bogers AJJC, Takkenberg JJM, Rutten-van Mölken MPMH.

Eur J Cardiothorac Surg. 2019 Apr 1;55(4):751-759. doi: 10.1093/ejcts/ezy382.

PMID:
30496373
9.

Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis.

Alemao E, Al MJ, Boonen AA, Stevenson MD, Verstappen SMM, Michaud K, Weinblatt ME, Rutten-van Mölken MPMH.

PLoS One. 2018 Oct 5;13(10):e0205013. doi: 10.1371/journal.pone.0205013. eCollection 2018.

10.

Defining good health and care from the perspective of persons with multimorbidity: results from a qualitative study of focus groups in eight European countries.

Leijten FRM, Hoedemakers M, Struckmann V, Kraus M, Cheraghi-Sohi S, Zemplényi A, Ervik R, Vallvé C, Huiĉ M, Czypionka T, Boland M, Rutten-van Mölken MPMH; SELFIE consortium.

BMJ Open. 2018 Aug 30;8(8):e021072. doi: 10.1136/bmjopen-2017-021072.

11.

How much does a heart valve implantation cost and what are the health care costs afterwards?

Huygens SA, Goossens LMA, van Erkelens JA, Takkenberg JJM, Rutten-van Mölken MPMH.

Open Heart. 2018 Feb 14;5(1):e000672. doi: 10.1136/openhrt-2017-000672. eCollection 2018. Erratum in: Open Heart. 2018 Apr 5;5(1):e000672corr1.

12.

ABC Index: quantifying experienced burden of COPD in a discrete choice experiment and predicting costs.

Goossens LMA, Rutten-van Mölken MPMH, Boland MRS, Donkers B, Jonker MF, Slok AHM, Salomé PL, van Schayck OCP, In 't Veen JCCM, Stolk EA; research team that developed the ABC tool.

BMJ Open. 2017 Dec 26;7(12):e017831. doi: 10.1136/bmjopen-2017-017831.

13.

Cost Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines.

Ramos IC, Versteegh MM, de Boer RA, Koenders JMA, Linssen GCM, Meeder JG, Rutten-van Mölken MPMH.

Value Health. 2017 Dec;20(10):1260-1269. doi: 10.1016/j.jval.2017.05.013. Epub 2017 Jun 20.

14.

Prediction models for exacerbations in different COPD patient populations: comparing results of five large data sources.

Hoogendoorn M, Feenstra TL, Boland M, Briggs AH, Borg S, Jansson SA, Risebrough NA, Slejko JF, Rutten-van Mölken MP.

Int J Chron Obstruct Pulmon Dis. 2017 Nov 1;12:3183-3194. doi: 10.2147/COPD.S142378. eCollection 2017.

15.

Assessment of Burden of COPD tool: evidence not perception.

Slok AHM, Kotz D, van Breukelen G, Chavannes NH, Rutten-van Mölken MPMH, Kerstjens HAM, van der Molen T, Asijee GM, Dekhuijzen PNR, Holverda S, Salomé PL, Goossens LMA, Twellaar M, In 't Veen JCCM, van Schayck OCP.

Eur Respir J. 2017 Jul 27;50(1). pii: 1700756. doi: 10.1183/13993003.00756-2017. Print 2017 Jul. No abstract available.

16.

External Validation of Health Economic Decision Models for Chronic Obstructive Pulmonary Disease (COPD): Report of the Third COPD Modeling Meeting.

Hoogendoorn M, Feenstra TL, Asukai Y, Briggs AH, Hansen RN, Leidl R, Risebrough N, Samyshkin Y, Wacker M, Rutten-van Mölken MP.

Value Health. 2017 Mar;20(3):397-403. doi: 10.1016/j.jval.2016.10.016. Epub 2017 Jan 3.

17.

Systematic review of model-based economic evaluations of heart valve implantations.

Huygens SA, Takkenberg JJM, Rutten-van Mölken MPMH.

Eur J Health Econ. 2018 Mar;19(2):241-255. doi: 10.1007/s10198-017-0880-z. Epub 2017 Mar 6. Review.

18.

Mix and match. A simulation study on the impact of mixed-treatment comparison methods on health-economic outcomes.

Vemer P, Al MJ, Oppe M, Rutten-van Mölken MP.

PLoS One. 2017 Feb 2;12(2):e0171292. doi: 10.1371/journal.pone.0171292. eCollection 2017.

19.

Comprehensive Diagnostic Assessment of Health Status of Patients with Asthma or COPD: A Delphi Panel Study among Dutch Experts.

van den Akker EF, Van't Hul AJ, Birnie E, Chavannes NH, Rutten-van Mölken MP, In't Veen JC.

COPD. 2017 Apr;14(2):190-199. doi: 10.1080/15412555.2016.1264378. Epub 2016 Dec 27.

PMID:
28026983
20.

'To use or not to use': a qualitative study to evaluate experiences of healthcare providers and patients with the assessment of burden of COPD (ABC) tool.

Slok AH, Twellaar M, Jutbo L, Kotz D, Chavannes NH, Holverda S, Salomé PL, Dekhuijzen PN, Rutten-van Mölken MP, Schuiten D, In 't Veen JC, van Schayck OC.

NPJ Prim Care Respir Med. 2016 Nov 17;26:16074. doi: 10.1038/npjpcrm.2016.74.

21.

Conceptual model for early health technology assessment of current and novel heart valve interventions.

Huygens SA, Rutten-van Mölken MP, Bekkers JA, Bogers AJ, Bouten CV, Chamuleau SA, de Jaegere PP, Kappetein AP, Kluin J, van Mieghem NM, Versteegh MI, Witsenburg M, Takkenberg JJ.

Open Heart. 2016 Oct 14;3(2):e000500. eCollection 2016.

22.

[Effectiveness of the Assessment of Burden of COPD tool: a cluster-randomised controlled trial].

van Schayck OC, Slok AH, Kotz D, van Breukelen G, Chavannes NH, Rutten-van Mölken MP, Kerstjens HA, van der Molen T, Asijee GM, Dekhuijzen PN, Holverda S, Salomé PL, Goossens LM, Twellaar M, In 't Veen JC.

Ned Tijdschr Geneeskd. 2016;160:D955. Dutch.

PMID:
27805538
23.

Patient Heterogeneity in Health Economic Decision Models for Chronic Obstructive Pulmonary Disease: Are Current Models Suitable to Evaluate Personalized Medicine?

Hoogendoorn M, Feenstra TL, Asukai Y, Briggs AH, Borg S, Dal Negro RW, Hansen RN, Jansson SA, Leidl R, Risebrough N, Samyshkin Y, Wacker ME, Rutten-van Mölken MPMH.

Value Health. 2016 Sep - Oct;19(6):800-810. doi: 10.1016/j.jval.2016.04.002. Epub 2016 May 21.

24.

Systematic Review and Quality Appraisal of Cost-Effectiveness Analyses of Pharmacologic Maintenance Treatment for Chronic Obstructive Pulmonary Disease: Methodological Considerations and Recommendations.

van der Schans S, Goossens LMA, Boland MRS, Kocks JWH, Postma MJ, van Boven JFM, Rutten-van Mölken MPMH.

Pharmacoeconomics. 2017 Jan;35(1):43-63. doi: 10.1007/s40273-016-0448-2. Review.

25.

Development of a Conceptual Model of Disease Progression for Use in Economic Modeling of Chronic Obstructive Pulmonary Disease.

Tabberer M, Gonzalez-McQuire S, Muellerova H, Briggs AH, Rutten-van Mölken MPMH, Chambers M, Lomas DA.

Med Decis Making. 2017 May;37(4):440-452. doi: 10.1177/0272989X16662009. Epub 2016 Aug 2.

PMID:
27486218
26.

Effectiveness of the Assessment of Burden of COPD (ABC) tool on health-related quality of life in patients with COPD: a cluster randomised controlled trial in primary and hospital care.

Slok AH, Kotz D, van Breukelen G, Chavannes NH, Rutten-van Mölken MP, Kerstjens HA, van der Molen T, Asijee GM, Dekhuijzen PN, Holverda S, Salomé PL, Goossens LM, Twellaar M, In 't Veen JC, van Schayck OC.

BMJ Open. 2016 Jul 11;6(7):e011519. doi: 10.1136/bmjopen-2016-011519.

27.

Development of the Galaxy Chronic Obstructive Pulmonary Disease (COPD) Model Using Data from ECLIPSE: Internal Validation of a Linked-Equations Cohort Model.

Briggs AH, Baker T, Risebrough NA, Chambers M, Gonzalez-McQuire S, Ismaila AS, Exuzides A, Colby C, Tabberer M, Muellerova H, Locantore N, Rutten van Mölken MPMH, Lomas DA.

Med Decis Making. 2017 May;37(4):469-480. doi: 10.1177/0272989X16653118. Epub 2016 Jun 17.

PMID:
27317436
28.

A five-year model to assess the early cost-effectiveness of new diagnostic tests in the early diagnosis of rheumatoid arthritis.

Buisman LR, Luime JJ, Oppe M, Hazes JM, Rutten-van Mölken MP.

Arthritis Res Ther. 2016 Jun 10;18(1):135. doi: 10.1186/s13075-016-1020-3.

29.

e-Monitoring of Asthma Therapy to Improve Compliance in children (e-MATIC): a randomised controlled trial.

Vasbinder EC, Goossens LM, Rutten-van Mölken MP, de Winter BC, van Dijk L, Vulto AG, Blankman EI, Dahhan N, Veenstra-van Schie MT, Versteegh FG, Wolf BH, Janssens HM, van den Bemt PM.

Eur Respir J. 2016 Sep;48(3):758-67. doi: 10.1183/13993003.01698-2015. Epub 2016 May 26.

30.

Contemporary outcomes after surgical aortic valve replacement with bioprostheses and allografts: a systematic review and meta-analysis.

Huygens SA, Mokhles MM, Hanif M, Bekkers JA, Bogers AJ, Rutten-van Mölken MP, Takkenberg JJ.

Eur J Cardiothorac Surg. 2016 Oct;50(4):605-616. Epub 2016 Mar 29. Review.

31.

THE EARLY BIRD CATCHES THE WORM: EARLY COST-EFFECTIVENESS ANALYSIS OF NEW MEDICAL TESTS.

Buisman LR, Rutten-van Mölken MP, Postmus D, Luime JJ, Uyl-de Groot CA, Redekop WK.

Int J Technol Assess Health Care. 2016 Jan;32(1-2):46-53. doi: 10.1017/S0266462316000064. Epub 2016 Mar 22.

PMID:
27002226
32.

Impact of financial agreements in European chronic care on health care expenditure growth.

Tsiachristas A, Dikkers C, Boland MR, Rutten-van Mölken MP.

Health Policy. 2016 Apr;120(4):420-30. doi: 10.1016/j.healthpol.2016.02.012. Epub 2016 Mar 2.

PMID:
26971018
33.

The Assessment of Burden of COPD (ABC) Scale: A Reliable and Valid Questionnaire.

Slok AH, Bemelmans TC, Kotz D, van der Molen T, Kerstjens HA, In 't Veen JC, Chavannes NH, Asijee GM, Rutten-van Mölken MP, van Schayck OC.

COPD. 2016 Aug;13(4):431-8. doi: 10.3109/15412555.2015.1118025. Epub 2016 Jan 20.

PMID:
26788838
34.

Current and Future Incidence and Costs of Osteoporosis-Related Fractures in The Netherlands: Combining Claims Data with BMD Measurements.

Lötters FJ, van den Bergh JP, de Vries F, Rutten-van Mölken MP.

Calcif Tissue Int. 2016 Mar;98(3):235-43. doi: 10.1007/s00223-015-0089-z. Epub 2016 Jan 9.

35.

Cardiovascular risk factor management in patients with RA compared to matched non-RA patients.

Alemao E, Cawston H, Bourhis F, Al M, Rutten-van Mölken MP, Liao KP, Solomon DH.

Rheumatology (Oxford). 2016 May;55(5):809-16. doi: 10.1093/rheumatology/kev427. Epub 2015 Dec 24.

36.

Cost-Effectiveness of Disease Management Programs for Cardiovascular Risk and COPD in The Netherlands.

Tsiachristas A, Burgers L, Rutten-van Mölken MP.

Value Health. 2015 Dec;18(8):977-86. doi: 10.1016/j.jval.2015.07.007. Epub 2015 Sep 16.

37.

Exploring the variation in implementation of a COPD disease management programme and its impact on health outcomes: a post hoc analysis of the RECODE cluster randomised trial.

Boland MR, Kruis AL, Huygens SA, Tsiachristas A, Assendelft WJ, Gussekloo J, Blom CM, Chavannes NH, Rutten-van Mölken MP.

NPJ Prim Care Respir Med. 2015 Dec 17;25:15071. doi: 10.1038/npjpcrm.2015.71.

38.

Investigating the association between medication adherence and health-related quality of life in COPD: Methodological challenges when using a proxy measure of adherence.

Boland MR, van Boven JF, Kruis AL, Chavannes NH, van der Molen T, Goossens LM, Rutten-van Mölken MP.

Respir Med. 2016 Jan;110:34-45. doi: 10.1016/j.rmed.2015.11.008. Epub 2015 Nov 23.

39.

Development of an integral assessment approach of health status in patients with obstructive airway diseases: the CORONA study.

van den Akker EF, van 't Hul AJ, Chavannes NH, Braunstahl GJ, van Bruggen A, Rutten-van Mölken MP, In 't Veen JC.

Int J Chron Obstruct Pulmon Dis. 2015 Nov 6;10:2413-22. doi: 10.2147/COPD.S90680. eCollection 2015. Erratum in: Int J Chron Obstruct Pulmon Dis. 2016;11:191.

40.

Cost-Effectiveness Model for Evaluating New Diagnostic Tests in the Evaluation of Patients With Inflammatory Arthritis at Risk of Having Rheumatoid Arthritis.

Luime JJ, Buisman LR, Oppe M, Hazes JM, Rutten-van Mölken MP.

Arthritis Care Res (Hoboken). 2016 Jul;68(7):927-35. doi: 10.1002/acr.22776.

41.

Performance Score Extraction from Panel Data for Multi-Criteria Decision Analysis (Mcda) Using a Regression-Based Approach.

Verbeek NA, Tsiachristas A, Franken M, Koopmanschap MA, Rutten-van Mölken MP.

Value Health. 2015 Nov;18(7):A718. doi: 10.1016/j.jval.2015.09.2717. Epub 2015 Oct 20. No abstract available.

42.

Assessing Copd Patients Burden Of Disease In A Fold-In-Fold-Out Discrete Choice Experiment.

Goossens LM, Stolk EA, Donkers B, Boland MR, Rutten-van Mölken MP.

Value Health. 2015 Nov;18(7):A503. doi: 10.1016/j.jval.2015.09.1430. Epub 2015 Oct 20. No abstract available.

43.

A Triple Aim Framework For The Performance Assessment Of Disease Management Programs.

Verbeek NA, Franken M, Tsiachristas A, Koopmanschap MA, Rutten-van Mölken MP.

Value Health. 2015 Nov;18(7):A400. doi: 10.1016/j.jval.2015.09.920. Epub 2015 Oct 20. No abstract available.

44.

Development Of A Conceptual Model For Early Health Technology Assessment Of Tissue-Engineered Heart Valves.

Huygens SA, Rutten-van Mölken MP, Bekkers JA, Bogers AJ, Bouten CV, Chamuleau SA, de Jaegere PP, Kappetein AP, Kluin J, van Mieghem NM, Versteegh MI, Witsenburg M, Takkenberg JJ.

Value Health. 2015 Nov;18(7):A394. doi: 10.1016/j.jval.2015.09.884. Epub 2015 Oct 20. No abstract available.

45.

A Five-Year Model to Assess The Cost-Effectiveness of New Diagnostic Tests In The Early Diagnosis of Rheumatoid Arthritis.

Buisman LR, Luime JJ, Oppe M, Hazes JM, Rutten-van Mölken MP.

Value Health. 2015 Nov;18(7):A358-9. doi: 10.1016/j.jval.2015.09.684. Epub 2015 Oct 20. No abstract available.

46.

Cost-effectiveness of integrated COPD care: the RECODE cluster randomised trial.

Boland MR, Kruis AL, Tsiachristas A, Assendelft WJ, Gussekloo J, Blom CM, Chavannes NH, Rutten-van Mölken MP.

BMJ Open. 2015 Nov 1;5(10):e007284. doi: 10.1136/bmjopen-2014-007284.

47.

Statistical Modeling of Disease Progression for Chronic Obstructive Pulmonary Disease Using Data from the ECLIPSE Study.

Exuzides A, Colby C, Briggs AH, Lomas DA, Rutten-van Mölken MPMH, Tabberer M, Chambers M, Muellerova H, Locantore N, Risebrough NA, Ismaila AS, Gonzalez-McQuire S.

Med Decis Making. 2017 May;37(4):453-468. doi: 10.1177/0272989X15610781. Epub 2015 Oct 8.

PMID:
26449490
48.

Cost-Effectiveness of Including a Nurse Specialist in the Treatment of Urinary Incontinence in Primary Care in the Netherlands.

Holtzer-Goor KM, Gaultney JG, van Houten P, Wagg AS, Huygens SA, Nielen MM, Albers-Heitner CP, Redekop WK, Rutten-van Mölken MP, Al MJ.

PLoS One. 2015 Oct 1;10(10):e0138225. doi: 10.1371/journal.pone.0138225. eCollection 2015.

49.

A conceptual disease model for adult Pompe disease.

Kanters TA, Redekop WK, Rutten-Van Mölken MP, Kruijshaar ME, Güngör D, van der Ploeg AT, Hakkaart L.

Orphanet J Rare Dis. 2015 Sep 15;10:112. doi: 10.1186/s13023-015-0334-6.

50.

Cost comparison of two implantable cardiac monitors in two different settings: Reveal XT in a catheterization laboratory vs. Reveal LINQ in a procedure room.

Kanters TA, Wolff C, Boyson D, Kouakam C, Dinh T, Hakkaart L, Rutten-Van Mölken MP.

Europace. 2016 Jun;18(6):919-24. doi: 10.1093/europace/euv217. Epub 2015 Aug 19.

PMID:
26293624

Supplemental Content

Loading ...
Support Center